Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
429 Leser
Artikel bewerten:
(1)

Cloud DX Inc.: Cloud DX Announces Commencement of Trading on the Toronto Venture Exchange

Finanznachrichten News

TORONTO, ON / ACCESSWIRE / April 14, 2021 / Cloud DX Inc. (TSXV:CDX) ("Cloud DX" or the "Company") is pleased to announce the commencement of trading on Thursday April 15th, 2021, on TSX Venture Exchange under the ticker symbol CDX. The Company's listing is the result of the successful Qualifying Transaction (as defined in the CPC Policy) with Roosevelt Capital Group Inc. which included an oversubscribed brokered private placement of approximately $6.1 million CAD.

"The board, management and in fact the whole team at Cloud DX is pleased that we have achieved this important milestone," said Robert Kaul, Founder & CEO of the Company. "This is another important step in the six and a half year mission at Cloud DX to make healthcare better for everyone, by improving the availability, efficacy and ease of use of virtual care and remote patient monitoring."

About Cloud DX

Cloud DX is a leader in virtual healthcare and digital medicine with rapidly growing sales across North America. Our complete remote patient monitoring platform incorporates proprietary medical devices, mobile apps, clinical dashboards, artificial intelligence and EMR integration. Cloud DX now provides products and services to hospitals, healthcare providers and provincial health departments across North America. In 2020, Cloud DX was a co-recipient of the Roche COVID Challenge award and is widely recognized for their ground-breaking med-tech innovations, including winning the Qualcomm Tricorder XPRIZE Bold Epic Innovator Award, Fast Company magazine "World Changing Idea" and most recently a 2021 Edison Award.

For further information, please contact:

Jay J. Bedard
Manager of Investor Relations
Cloud DX Inc.
Telephone: 647-881-8418
Email: investor.relations@clouddx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the content of this press release.

Caution Regarding Forward-Looking Statements

This news release includes certain forward-looking statements, which may include but are not limited to, statements with respect to obtaining the final bulletin from the Exchange. Such statements are based on the current opinions and expectations of management of the Company. The forward-looking events and circumstances discussed in this release, including receipt of the final Exchange bulletin, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements herein, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statements can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/640272/Cloud-DX-Announces-Commencement-of-Trading-on-the-Toronto-Venture-Exchange

© 2021 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.